clinical trial · NCT07906639
A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor
Primary Biliary Cholangitis (PBC)Elafibranor
brief summary
The purpose of this study is to understand how tiredness changes in adults with Primary Biliary Cholangitis (PBC) after starting elafibranor in routine clinical practice. PBC is a rare liver disease that damages the small bile ducts in the liver. Participants will complete questionnaires before starting elafibranor and at Months 3, 6 and 12. The questionnaires will ask about tiredness, itching, work and daily activities. Each participant will be followed for approximately 12 months.
started
Nov 2, 2026
primary completion
Aug 21, 2028
completion
Aug 21, 2028
last updated
Oct 30, 2026
official title
Prospective Observational Study Assessing the Impact of Elafibranor on Fatigue, Work Productivity/Activity Impairment, and Pruritus in Patients With PBC
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol